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Summary. Since cyelosporin A (CsA) is an immuno- 
suppressive agent, its beneficial effect in psoriasis 
suggests that immune cells may play a role in the patho- 
genesis and resolution of psoriasis. To determine early 
effects of CsA in psoriasis, we quantitated immune cells 
using double immunofluorescence microscopy on biopsy 
specimens obtained prior to therapy and after 3,7, and 
14 days of CsA therapy. CsA therapy resulted in signifi- 
cant reductions in the absolute number of immune cells 
(including T cells, monocytes[macrophages, and antigen 
presenting cells) contained within psoriatic skin. The 
effect was rapid, with over one-half of the reduction 
in the density of HLe l  § (human leukocyte antigen-1 
positive or bone marrow derived) cells, including T cells, 
activated T cells, monocytes, and Langerhans cells 
(LCs), occurring within 3 days. Despite the overall re- 
duction in the numbers of immunocytes in the skin, the 
proportion of T cells, Langerhans cells, and monocytes 
in relation to the total number of immune cells was 
unchanged with therapy, reflecting equally proportional 
losses of each subtype. Dermal CD1 +DR + cells (puta- 
tive Langerhans cells), which are not found in normal 
skin but are present in lesional psoriasis skin, were 
virtually cleared from the papillary dermis after CsA 
therapy. Although absolute numbers of epidermal 
Langerhans cells, defined as cells expressing both CD1 
(T6) and DR molecules (CD1 + DR +), were also reduced 
after CsA, epidermal non-Langerhans CD1-DR + cells 
(macrophages, activated T cells, D R -  keratinocytes) 
demonstrated a proportionally greater decrease, with 
the ratio of CDI+DR + Langerhans cells]non-Langer- 
hans CD1-DR + epidermal cells changing from a mean 
of 0.82 at baseline to 1.92 at day 14. Thus, early in the 
course of therapy, CsA appears to be effective at clear- 
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ing CD1-DR + cells while leaving LC relatively intact 
in the epidermis. 
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Psoriasis is a common inflammatory disorder, 
probably of multifactorial etiology, affecting approx- 
imately 2% of the population in the United States 
of America. We recently carried out a randomized, 
double-blind trial in which cyclosporine A (CsA), 
administered at a dose of 14 mg/kg/day, caused dra- 
matic improvement in 20 of 21 psoriatic patients 
within 4 weeks [1]. Since CsA has immunosuppressive 
effects, this raised the possibility that cellular immune 
processes may play a role in the pathophysiology of 
psoriasis. Analysis of changes in immune cellular el- 
ements present in lesional psoriasis skin may help 
elucidate the mechanism of action of CsA in psoriasis. 
In six consecutive patients, we performed quanti- 
tative single and double immunofluorescence mi- 
croscopy using monoclonal antibodies directed to- 
ward leukocyte subsets in order to characterize im- 
mune cellular changes that occur within the epidermal 
and dermal infiltrate at various times after initiation 
of oral CsA therapy. Baker et al. [2] have looked at 
changes in immune cell types in psoriatic lesions 
treated with CsA at time intervals ranging between 10 
and 90 days after CsA therapy. Since we saw clinical 
improvement in most patients by 10 days of CsA ther- 
apy (14 mg/kg/day) [I], we decided to investigate the 
changes in immune cell types prior to clinical improve- 
ment being obvious. In addition, we correlated clinical 
improvement with the nature and flux of the infiltrate. 
Here, we report that CsA induces changes in activated 
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T cells, antigen presenting cells (APCs) and mono-  
cytes, expressed as bo th  absolute density o f  cells in the 
tissue and as relative percentages o f  total  leukocytes 
within 7 days o f  CsA therapy. 
Materials and methods 
Patients 
Six consecutive patients (all males), treated with CsA 14 mg/kg/ 
day for 4 weeks, were studied for immunophenotype analysis. 
Their mean age was 45 years (range, 32 to 61 years). Patients 
had greater than 20% body surface area involved and had been 
unresponsive to conventional therapies. The psoriasis had been 
stable in extent and severity for at least 2 weeks. The patients had 
not used systemic or intralesional corticosteroids, or ultraviolet 
(UVB or PUVA) therapy for at least 4 weeks, nor topical ther- 
apy, except bland emmolients, for at least 2 weeks prior to entry 
into the study. Patients were at least 18 years old and in good 
health on the basis of history and physical examination. Clinical 
evaluation of psoriasis was made at pretherapy, after the 3rd 
and 7th days of therapy, and then at weekly intervals. 
The protocol and consent had been approved by the Univer- 
sity of Michigan Medical Center institutional review board. The 
Food and Drug Administration had approved our physician's 
investigational drug application. All the patients gave informed 
consent after the nature of the study had been fully explained. 
the primary antibody (first step) which was visualized with 
rhodamine-conjugated goat anti-mouse IgG (second step) and 
then a second directly fluoresceinated antibody to a separate 
determinant was mixed with normal mouse serum and applied 
to the tissue (third step). The mouse serum prevents binding of 
the rhodamine goat anti-mouse IgG antibody to the third step 
antibody. The sections were coverslipped in PBS containing 
50% glycerol and visualized using a Nikon Optiphot microscope 
equipped with epifluorescence, appropriate filters, and double 
exposure photographic capabilities. For each specimen, the den- 
sity of cells stained by the various monoclonal antibodies was 
counted in at least 10 high power fields (hpf; 1.4 linear mm of 
skin) and the average obtained. When sections stained with anti- 
CD1 antibody were examined, only dendritic cells exhibiting 
the cytoplasm and nucleus were counted as positive; dendrites 
without the main cell body were not included [19]. 
Statistical evaluation 
In order to determine whether the degree of infiltrate (absolute 
density per mm) of the various phenotypes had changed signifi- 
cantly between baseline and days 3 and 7, a paired t-test was 
used. This test was also used to evaluate whether the phenoffpes 
Monol, Leul, Leul+DR +, CDI+DR +, and CD1-DR + ex- 
pressed as a ratio of HLel +, had changed significantly between 
baseline and day 7. We also determined, using Pearson's corre- 
lation analysis, whether there was a relationship between clinical 
lesion scores and a change in certain cell phenotypes. Allp values 
are two-sided unless otherwise stated. 
Fluorescence microscopy 
In 3 patients, 6-mm punch biopsy specimens were taken from 
representative psoriatic plaques at pretherapy and after 3 and 
7 days of CsA therapy, and in three patients at pretherapy and 
after 7 and 14 days. Punch biopsy specimens were obtained 
following local anesthesia with 1% lidocaine with epinephrine. 
These were embedded in Tissue Tek II O.C.T. compound (Miles 
Laboratories, Naperville, Ill.) and were rapidly frozen and stored 
at - 7 0  ~ C. Subsequently, 6-1am sections were cut on a cryostat, 
mounted on albuminized slides, and air dried. 
In order to determine the type and intensity of the epidermal 
and dermal infiltrate, a battery of monoclonal antibodies was 
employed. HLel is a surface antigen expressed on all human 
bone marrow derived cells (leukocytes; Becton Dickinson, 
Mountainview, Calif). Leul detects a pan T cell antigen (CD5) 
on human peripheral and thymic T cells (Becton Dickinson). 
OKT6 stains the cell-surface antigen CD 1 on cortical thymocytes 
and Langerhans cells (LCs; Ortho Diagnostic Systems). Anti 
HLA-DR (Becton Dickinson) binds to class II major histo- 
compatibility complex proteins of LCs, B cells, activated T cells, 
monocytes, and interferon gamma-exposed keratinocytes. 
Monol is a monocyte antigen marker (Bethesda Research Lab- 
oratories (BRL), Bethesda, Md.). 
For single label immunofluorescence, 6-~tm frozen sections 
of psoriatic tissue were incubated with optimal dilutions of the 
primary antibody for 45 min at room temperature, washed three 
times in phosphate-buffered saline (PBS) at pH 7.6, followed by 
a 30-min incubation with second step fluorescein-conjugated 
antibody (goat anti-mouse IgG antibody, heavy and light chain 
specific, affinity purified and human serum adsorbed; 
Kirkegaard and Perry, Gaithersburg, Md.). For double label 
immunofluorescence microscopy, one primary antibody was 
fluoreseein-conjugated and the other primary antibody was 
biotin-conjugated. The second step reagent was Texas Red con- 
jugated to streptavidin (Bethesda Research Laboratories). In 
some cases, a three-step method was used, which consisted of 
Results 
The mean  number  o f  cells/hpf in the epidermis and  
dermis o f  the six patients at days 0 (baseline) and 7 o f  
CsA therapy is shown in Figs. 1 and  2 respectively. 
Lesional  psoriasis skin conta ined a large number  and 
variety o f  infiltrating leukocytes. In  addi t ion to LCs, 
non-Langerhans  CD1 - D R  + cells were present in pso- 
riasis epidermis (Fig. 3a, b). H L e l  + cells (bone 
marrow-der ived  leukocytes) were present in the epi- 
dermis and dermis, and were comprised o f  Leul  + T 
cells (Fig. 4a,  b), activated ( D R  +) T cells (Fig. 5a, b) 
and m o n o c y t e / m a c r o p h a g e  derived cells (Fig. 5 c). 
CsA therapy resulted in a marked  decrease in these 
cell types f rom the skin (Figs. 4c,  d and 5 d -  f). Absol-  
ute cell counts  o f  each pheno type  were per formed 
to quant i ta te  the degree o f  clearing (Figs. 1 and 2). 
Between days 0 and 7, in the epidermis, there was a 
significant decrease (p < 0.01) o f  bone  marrow-de-  
rived cells, whether  calculated as the number  o f  
H L e l  + cells or  as the total o f  Leu l ,  M o n o l  and 
CD1 + D R  + cells. There were also significant decreases 
in the number  o f  H L e l  - D R  + keratinocytes,  M o n o l  + 
macrophages ,  Leu l  + T cells, L e u l + D R  + activated 
T cells, C D I + D R  + LCs and non-Lange rhans  
C D 1 - D R  + cells (Fig. 1). 
In  the epidermis, H L e l - D R  + cells identify 
keratinocytes,  p resumably  induced by gamma-in ter -  
feron to express H L A - D R .  These decreased by 47% 













10 .  
0 "  
Day 0 7 0 7 0 7 0 7 




0 7 0 7 
Leul+DR+ HLel-DR+ 
Fig. 1. Absolute number of cells of 
the various phenotypes in the epi- 
dermis before and after 7 days of 
CsA therapy. Number of  cells ex- 
pressed per hpf (linear 1.4 ram) 
+ SEM (n = 6). * p < 0.05, 
9 * p < 0.001 
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Fig. 2. Absolute number of cells of 
the various phenotypes in the der- 
mis before and after 7 days of CsA 
therapy. Number of cells expressed 
per hpf (linear 1.4 ram) + SEM 
(n = 6), * p < 0.05, ** p < 0.001 
Fig. 3a, b. Expression of CDI(T6) (a) and HLA-DR (b) at pre- 
therapy. Small arrows denote epidermal Langerhans cells ex- 
pressing both CDI(T6) (a) and HLA-DR (b). Large arrow de- 
note cells expressing HLA-DR (b) but not CDI(T6) (a). These 
include macrophages, indeterminate cells and activated T cells. 
(Original magnification x 50) 
over the 1st week of  therapy. Within the epidermal 
C D I - D R  + population are contained activated T 
cells, keratinocytes, indeterminate cells, and 
macrophages (Fig. 3a, b). These decreased by 59% 
between days 0 and 7 of  CsA therapy. By day 14, 
epidermal non-Langerhans CD1-  DR + cells demon- 
strated a proportionally greater decrease than did 
CD1 +DR + LCs, with the ratio of  CD1 +DR + LCs to 
C D I - D R  § cells changing from a mean of  0.82 at 
baseline to 1.92 at day 14. 
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Fig. 4 a - d .  Distribution of infiltrating leukocytes contained in 
involved psoriasis skin at pretherapy a,b and after 14 days of 
CsA therapy e, d. (Original magnification x 50); a Intense infil- 
trate of HLel + (bone marrow derived) and b Leul + (T cells) in 
psoriasis skin at pretherapy. Open arrows denote cells expressing 
both HLel a and Leul b. (HLel +Leul + cells). Closed arrows 
denote cells expressing HLel a but not Leul b. (HLel +Leul- 
cells). These include macrophages and Langerhans cells, e 
Marked reduction in infiltrate of HLel + (bone marrow derived) 
cells and d Leul + (T cells) at day 14 of CsA therapy. Open arrows 
denote cells expressing both HLel a and Leul b. (HLel + Leul +T 
cells). Closed arrows denote cells expressing HLel a but not 
Leul b. (HLel + Leul- cells). These include macrophages and 
Langerhans cells 
In the dermis at day 0, bone marrow derived cells 
(HLel  +) were comprised of  monocytes, T cells and 
C D I + D R  + cells which may be Langerhans cells 
(Figs. 2, 3). As in the epidermis, significant reductions 
in the absolute numbers of  infiltrating cells in the 
dermis were observed after CsA therapy. Compared 
with untreated psoriasis skin, the absolute numbers 
of  dermal CD1 +DR + Langerhans cells decreased by 
66% over the 1st week of CsA therapy, and by day 7 
of therapy, these cells were rarely seen. Although the 
density of  all T cells was reduced at day 7 (Fig. 2), the 
mean percentage decrease of activated T cells 
(DR+Leul  +) was only 30%, compared to a 66% de- 
crease of  nonactivated T cells ( D R - L e u  + ; p < 0.05). 
Persistence of  DR+Leu l  + T cells was also observed 
in the epidermis. 
If clearing of  immunocytes from the skin is 
important  to the mechanism of CsA action in pso- 
riasis, then the cells should show a brisk response 
which is followed by clinical improvement. In order 
to assess the rapidity of disappearance of  individual 
cell types, changes in the absolute numbers of  cells/ 
hpf  between pretherapy and days 3, 7, and 14 were 
expressed as the percent decrease in the absolute num- 
bers of  cells/hpf relative to day 0. For  example, the 
percentage decrease in Leul  cells at days 3, 7, and 14 
of therapy were 42%, 49%, and 61% respectively. The 
majority of  the loss of  leukocytes (Leu 1 +, Mono I +, 
and C D 1 - D R  +) occurred within the first 3 days of 
CsA therapy (mean decrease that occurred during the 
first 3 days expressed as a percentage of  the decrease 
that had occurred during the first 14 days of  therapy 
was 63 %). DR + keratinocytes (HLe 1 - DR +) demon- 
strated a somewhat slower decrease in the absolute 
numbers of  cells per hpf  relative to baseline of  30%, 
52%, and 86% at days 3, 7, and 14 of  CsA therapy 
respectively. 
Clinical lesion scores demonstrated a 30%, 52%, 
and 70% decrease (relative to pretherapy) at days 3, 
7, and 14, respectively, following CsA therapy. Thus, 
although it is difficult to compare clinical lesion score 
data with cellular immunopathology quantitations, it 
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F i g .  5 a - f. Distribution of immunocytes at pretherapy a -  e and 
after 7 days of CsA therapy d - f ;  original magnification x 50. 
a Leul + (T cells) and b DR + cells in psoriasis skin at pretherapy. 
Small arrows denote cells expressing both Leul a and HLA-DR 
b (Leul +DR + cells; activated T cells). Curved arrows denote 
cells expressing Leul a but not HLA-DR b (LeuI+DR cells; 
non-activated T cells). Open arrows denote cells expressing HLA- 
DR b but not Leul a (Leul DR + cells). These include 
Langerhans cells and macrophages, e Mono 1 + monocytic cells 
in psoriasis skin at pretherapy (small arrows), d Marked decrease 
in Leul + (T cells) and e DR + cells at day 7 of CsA therapy. 
Small arrows denote cells expressing both Leul a and HLA-DR 
b (Leul+DR + cells; activated T cells). Curved arrows denote 
cells expressing Leul a but not HLA-DR b (Leul +DR cells; 
non-activated T cells). Open arrows denote cells expressing H LA- 
DR b but not Leul a (LeuI-DR + cells). These include 
Langerhans cells and macrophages, f Very few monocytes re- 
main at day 7 of CsA therapy (small arrows) 
appea r s  tha t  c lear ing  o f  i m m u n e  cells occurs  at  least  
concomi tan t ly ,  and  pe rhaps  p r io r  to cl inical  reso-  
lut ion.  
I m m u n e  cells a n d  thei r  func t ions  va ry  cons ide r -  
ab ly  in their  sensi t ivi ty  to CsA.  To de t e rmine  i f  there  
was selective d i s a p p e a r a n c e  o f  cer ta in  C s A  sensit ive 
cell types,  the p r o p o r t i o n  o f  the d i f ferent  cell types  at  
va r ious  t imes du r ing  t r ea tmen t  was de t e rmined  rela-  
tive to the c o r r e s p o n d i n g  to ta l  n u m b e r  o f  leukocytes .  
There  was no s ignif icant  difference be tween base l ine  
a n d  d a y  7 o f  t h e r a p y  in the n u m b e r  o f M o n o l  + m o n o -  
cytes expressed as a pe rcen tage  o f  the to ta l  n u m b e r  o f  
leukocytes  in the lesion (Table  1). The  same was t rue 
for  L e u l  + T cells, ac t iva t ed  T cells ( L e u l  + D R  +) and  
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Table 1. Leukocyte subsets at pretherapy (day 0) and 7 days of CsA therapy expressed as a percentage of the total number of 
leukocytes in the psoriatic lesion 
Phenotype Epidermis Dermis 
Day 0" Day 7 p value b Day 0 Day 7 p value 
Monol + 39.0 + 1.6 c 43.0 _+ 0.6 NS d 48,0 _+ 3.0 49.4 _+ 2.5 NS 
Leul + 37.0 + 0.9 32.8 +_ 1.6 NS 49.4 _+ 3.4 43.2 + 1.5 NS 
Leul +DR + 16.0 +_ 5.4 17.6 _+ 3.8 NS 21.4 -t- 2.5 25.2 +_ 4.0 NS 
CD1 +DR + 24.2 + 1.1 24.0 + 1.6 NS 7.2 + 0.6 7.2 -I- 1.0 NS 
CDI -DR + 28.2 _+ 1.9 19.6 _+ 1.5 0.04 53.8 _+ 5.4 45.0 -t- 2.6 NS 
" Day of biopsy following onset of therapy with CsA 
b Values refer to changes between baseline and day 7 of CsA therapy 
c Values expressed as a percentage mean + SEM of 6 patients 
a NS, Not significant (p > 0.05) 
C D I + D R  + LCs (Table1). For  the phenotype 
C D 1 - D R  + in the epidermis, there was a significant 
decrease (p = 0.04) in the number of  cells of  this sub- 
type expressed as a percentage of  total leukocytes 
between days 0 and 7 of  therapy, confirming that LCs 
tended to emerge as the predominant DR + cell in 
treated epidermis (Table 1). 
Discussion 
There is a marked difference in the composition of  the 
various cell types in psoriatic epidermis and dermis 
compared with normal skin. Bone marrow derived 
cells in the normal human epidermis consist almost 
entirely of  LCs [ 4 -  6]. These LCs normally comprise 
1 % -  4% percent of the total epidermal population 
[5, 7]. In our untreated patients, leukocytes in the epi- 
dermis of  involved psoriasis skin were composed of  
CDI +DR + LCs, Mono l  + macrophages and Leul  + 
cells (Fig. 1). In a study by Baker et al. [10], epidermal 
leukocytes in psoriasis skin were also elevated and 
contained both T cells and DR + dendritic cells 
( C D I + D R  + LCs and C D 1 - D R  + epidermal cells). 
Utilizing epidermal cell suspensions, we have pre- 
viously shown that psoriatic epidermal cells contain 
an elevated capacity to activate T cells [8]. The 
C D 1 - D R  + cells in psoriatic epidermis appear to be 
antigen presenting cells, since both C D 1 - D R  + cells 
as well as CD1 +DR + LCs, were critical for the induc- 
tion of T cell activation [8]. In the normal dermis, 
bone marrow derived cells are usually comprised of 
monocytes and macrophages [9], as well as a small 
number of  T cells [10]. We found that leukocytes in the 
dermis of  psoriatic plaques consisted of  approximately 
equal proportions of  T cells and cells of the monocyte/  
macrophage series, along with an increased pro- 
portion of  C D I + D R  + LCs (which are only rarely 
present in normal dermis). Other authors [11, 12] have 
also found that the dermal infiltrate in early and fully 
developed psoriatic lesions consists mostly of  T~ lym- 
phocytes and macrophages, with the former being the 
predominant cell type. 
CsA therapy caused a marked decrease in the in- 
tensity of  the immunocytic infiltrate in both the epider- 
mis and dermis. There was a significant decrease in the 
number of  all subsets of  leukocytes and in epidermal 
H L e l - D R  + keratinocytes. However, the proport ion 
of  T cells, activated T cells, monocytes, CD1 +DR + 
LCs and dermal C D 1 - D R  + cells in relation to the 
total number of  leukocytes was unchanged with ther- 
apy, reflecting equally proport ionate losses of  each 
subtype (Table I). The reduction in the absolute num- 
bers of total leukocytes, T cells, activated T cells, 
monocytes and C D I + D R  § LCs was rapid, with a 
large proport ion of  the change occurring within 3 
days. The rapidity of  the CsA effect on leukocyte 
reduction is consistent with the concept that the im- 
mune effects of  CsA are important  in the mechanism 
of  CsA clearing of  psoriasis, since leukocyte reduction 
either preceded or coincided with clinical improve- 
ment. 
In psoriatic epidermis, using double immunofluo- 
rescence techniques to visualize CD1 and HLA-DR,  
we found that the absolute numbers of  LCs decreased 
with CsA therapy, with the number and pattern of  
LCs in treated psoriatic epidermis being similar to that 
of  normal skin. Much attention has been focused on 
the number and location of  LCs in psoriasis; however, 
it remains controversial as to whether LCs in psoriasis 
lesions as assessed in vertical sections are increased 
relative to normal [13] or uninvolved psoriasis skin 
[13, 14], or decreased compared with normal [15, 16] 
or uninvolved psoriasis skin [14]. Comparison of  epi- 
dermal LCs density obtained by various authors [ 1 4 -  
19] is difficult because of  the large numbers of methods 
used to quantitate LCs in sections [2, 14, 15, 17, 20, 
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21]. Utilizing epidermal cell suspensions to quantitate 
CD1 +DR § LCs in relation to keratinocytes, we found 
no significant difference in the percentage of  
Langerhans cells in psoriasis epidermis relative to 
uninvolved epidermis [8]. As reported by Bos et al. 
[22], we found that LCs are present in significantly 
increased numbers in the dermis in untreated lesions 
of  psoriasis (Fig. 3), since LCs are only rarely present 
in normal dermis [10, 231. The presence of  dermal 
LCs in untreated psoriatic lesional skin supports the 
concept of psoriatic skin harboring a form of  an 
ongoing cellular immune response. Significant num- 
bers of  dermal LCs are generally only found in the 
context of  cellular immune responses in the skin (for 
example, allergic contact dermatitis) [24] or in cu- 
taneous T-cell lymphoma [25]. 
Unlike normal skin which lacks epidermal 
C D 1 - D R  + ceils [8, 22], in lesional psoriatic skin 
C D I - D R  + cells were present in the epidermis at day 
0. C D 1 - D R  + cells in the epidermis of  psoriatic skin 
are heterogenous [8] and contain a variety of  D R § 
cells, including activated T cells (DR § T lympho- 
cytes), activated keratinocytes (DR § keratinocytes), 
DR + monocytes and non-LCs dendritic APC [1, 8, 23]. 
CD 1 - DR § dendritic cells may contain immature LCs, 
since Birbeck granules have been found in certain 
of  these cells [9]. However, psoriasis epidermal 
C D I - D R  + cells may be analogous to non- 
Langerhans C D 1 - D R  + cells, reported following 
UVB and UVC radiation, that are potent stimulators 
of  immunoregulatory self-T cells in the absence of 
added antigen [ 2 6 -  29]. In fact, Schopf et al. [30] have 
demonstrated that epidermal cells from lesional psori- 
atic skin are significantly more active in stimulating 
autologous T cell proliferation compared with cells 
from uninvolved psoriatic or normal epidermis. Since 
C D 1 - D R  + epidermal cells are involved in the en- 
hanced antigen presenting activity of  psoriasis epider- 
mal cells [8], the CD1 - D R  + population may be critical 
for initiating T-cell activation and inflammatory 
lymphokine release in psoriasis skin. 
In the epidermis by day 7 of  therapy, both the 
absolute numbers of  CD1 - D R  + cells (Fig. 1) as well 
as the proport ion of  these cells as a percentage of  total 
leukocytes at day 7 was decreased (Table 1). We also 
noted a dramatic loss of  CDI - D R  + cells as well as 
antigen presenting cell function, in psoriasis epidermis 
during CsA therapy when quantitated using epidermal 
cell suspensions [31]. Epidermal non-Langerhans 
C D 1 - D R  + cells demonstrated a proportionally 
greater decrease compared to epidermal CDI +DR + 
LCs with the ratio of  C D I + D R  + LCs/non- 
Langerhans C D 1 - D R  + epidermal cells changing 
from a mean of  0.82 to 1.92 at day 14. Thus, CsA 
appears to be effective at clearing C D 1 - D R  + cells 
while leaving Langerhans cells relatively intact in the 
epidermis. 
Our findings of  a rapid reduction in T-cell numbers 
in psoriasis skin following CsA therapy are consistent 
with a role for T cells and their lymphokines in pso- 
riasis. Double staining with ant i -HLel  and ant i-HLA 
D R or anti-Leul and ant i -HLA D R monoclonal  anti- 
bodies confirmed that in lesional psoriatic epidermis, 
DR § keratinocytes are present in the vicinity o f T  cells 
in a basilar position [18, 32]. 
Psoriasis skin contains increased numbers of 
monocytes, Langerhans cells, and T cells, and shows 
evidence of  an ongoing cellular immune reaction. CsA 
may cause improvement of  psoriasis by interfering 
with immune cell activation in the skin. This is sup- 
ported by the decreased numbers of  inflammatory 
cells in both the epidermis and dermis, and evidence 
of reduced production of  proinflammatory cytokines 
early in the course of  treatment with CsA. 
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